The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce John Cherol, EGFR patient.
You may have noticed some frustrating server issues with GRACE these past few days. Our true apologies – we are working diligently with our provider...
You may have noticed some frustrating server issues with GRACE these past few days. Our true apologies – we are working diligently with our provider...
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce Sara Whitlock, RET + patient.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.